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Conclusion: The current study indicates that ADC mapping is 
the most promising MRI technique to predict the tumor 
location in the prostate based on TFA and therefore is 
absolute prerequisite for dose painting approaches in 
advanced adaptive radiotherapy (ART). 
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Purpose or Objective: Oropharyngeal squamous cell 
carcinoma (OPSCC) is one of the fastest growing head and 
neck cancers, for which human papillomavirus (HPV) status 
has been described as a strongly prognostic factor. Overall, 
prognosis is favorable for HPV positive (HPV+) patients, which 
makes this an interesting subgroup for de-escalation 
protocols. An established, non-invasive, imaging biomarker of 
HPV status currently does not exist. Radiomics–the high-
throughput extraction of large amounts of quantitative 
features from medical images–has already been shown to be 
of prognostic value for head and neck cancer. In this study 
we evaluate the use of a Radiomic approach to distinguish 
between HPV+ and HPV negative (HPV-) OPSCC patients. 
 
Material and Methods: A total of 542 patients with OPSCC, 
treated with curative intent between 2005 and 2010 were 
collected for this study. HPV status was determined by p16 
and available for 434 patients. Patients underwent pre-
treatment CT imaging and the tumor volume was manually 
delineated for treatment planning purposes. Images were 
visually assessed for the presence of CT artifacts (e.g. streak 
artifacts due to dental fillings) within the GTV, in which case 
they were excluded from further analysis. In total, 241 
Radiomic features were extracted, comprising: a) first-order 
statistics, b) shape, and c) (multiscale) texture by Laplacian 
of Gaussian filtering. The Radiomic feature space was first 
reduced by selecting cluster medoids after hierarchical 
cluster analysis using correlation (ρ>0.9) as a distance 
measure. Multivariable logistic regression was performed 
using least absolute shrinkage and selection operator (LASSO) 
model selection (100 times 10-fold cross-validated). The area 
under the receiver operator curve (AUC; 500 times 
bootstrapped) was used to assess out-of-sample model 
performance in predicting HPV status. 
 
Results: Out of the patients with known HPV scoring, we 
identified 211 (49%) patients without visible CT artifacts, of 
which 134 were HPV positive. The modeling process resulted 
in an eleven-feature multivariable prediction model. The 
overall receiver operator curve is shown in Figure 1. The 
bootstrapped AUC was on average 0.77 (95% CI: 0.73-0.80). 
 
 
Conclusion: Using a Radiomic approach, we were able to 
distinguish between HPV+ and HPV- OPSCC patients, using 
standard pre-treatment CT imaging. These results require 
further validation, but suggest the potential for a novel 
quantitative Radiomic biomarker of HPV status, facilitating 
personalized treatment selection. 
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MRI guidance for the radiation treatment of patients with 
cancer in the pelvic region has globally increased during the 
last two decades. MRI is used for staging, treatment planning, 
monitoring of treatment response and for disease observation 
during follow up. Consistent and repetitive use of MRI has 
provided insight into tumour and surrounding organ anatomy 
as well as their movements and deformations. In cervical 
cancer treatment, MRI guidance for brachytherapy treatment 
planning and dose delivery allowed better tailoring of the 
dose to the target, with higher tumour doses while sparing 
the organs at risk (OARs). However, the aimed dose for target 
and OARs may differ from the actually delivered dose due to 
movements and deformations of the OARs during HDR or PDR 
treatments. Several single institution reports describe that 
dose uncertainties caused by displacement and deformations 
of OARs are on average small, however individual outliers 
occur. Especially for the rectum higher delivered doses have 
been found in individual patients. In case of HDR 
brachytherapy, re-imaging prior to dose delivery can help to 
detect unfavourable anatomical changes, allowing for 
interventions that might help to stabilize dosimetry and 
prevent morbidity. The availability of MR imaging within the 
brachytherapy suite is an upcoming innovation that supports 
these types of adaptive brachytherapy approaches. The aim 
of the international ‘EMBRACE study’ 
(www.embracestudy.dk) was to introduce MRI based 
brachytherapy in a multicentre setting within a prospective 
observational setting and to correlate DVH parameters with 
outcome. Preliminary results from EMBRACE, from the 
retrospective ‘Retro-EMBRACE’ study 
(www.retroembrace.com) and from several single institution 
reports, revealed an increase in local control due to the use 
of MRI guidance. Brachytherapy treatment allows delivery of 
sterilizing doses to the primary cervical tumour, however, 
lymph node disease is getting the dose delivered by external 
beam radiotherapy treatment (EBRT). The upcoming 
prospective multicentre ‘EMBRACE II study’ will focus on 
advanced Image Guided and Adaptive EBRT (IGART) combined 
with MRI guided intracavitary/interstitial brachytherapy with 
